<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816983</url>
  </required_header>
  <id_info>
    <org_study_id>16-000785</org_study_id>
    <secondary_id>CA200551</secondary_id>
    <nct_id>NCT02816983</nct_id>
  </id_info>
  <brief_title>SBRT for Oligometastatic Castration-Refractory Prostate Cancer</brief_title>
  <official_title>A Phase II Evaluation of SBRT in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SBRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA)&#xD;
      are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions.&#xD;
      Patients with &lt;=3 metastatic lesions will receive stereotactic body radiotherapy (SBRT) as&#xD;
      definitive treatment. Blood draws will be taken to monitor the development of anti-prostate&#xD;
      cancer immunity&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PSA-progression free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT for oligometastatic prostate cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <arm_group_label>SBRT for oligometastatic prostate cancer</arm_group_label>
    <other_name>Stereotactic ablative radiotherapy (SABR)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must be receiving standard of care SBRT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be receiving standard of care SBRT as outlined in the Universal Content&#xD;
             Management (UCM) Procedure Manual&#xD;
             (http://mayocontent.mayo.edu/radoncology/categories/index.html)&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Metastatic castration-refractory prostate cancer patients with ≤ 3 lesions identified&#xD;
             on standard imaging and/or choline PET/CT within 60 days of registration&#xD;
&#xD;
          -  Castrate levels of testosterone&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 (Appendix I).&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Emergent cord compression for spinal metastases&#xD;
&#xD;
          -  Severe, active co-morbidity, defined as follows:&#xD;
&#xD;
               1. Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the last 6 months prior to registration&#xD;
&#xD;
               2. Transmural myocardial infarction within the last 6 months prior to registration&#xD;
&#xD;
               3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration&#xD;
&#xD;
               4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy within 30 days prior to&#xD;
                  registration&#xD;
&#xD;
               5. Severe hepatic disease, defined as a diagnosis of Child-Pugh Class B or C hepatic&#xD;
                  disease.&#xD;
&#xD;
               6. HIV positive with Cluster Differentiation 4 (CD4) count &lt; 200 cells/microliter.&#xD;
                  Note that patients who are HIV positive are eligible, provided they are under&#xD;
                  treatment with highly active antiretroviral therapy (HAART) and have a CD4 count&#xD;
                  ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV&#xD;
                  testing is not required for eligibility for this protocol.&#xD;
&#xD;
               7. End-stage renal disease (i.e., on dialysis or dialysis has been recommended).&#xD;
&#xD;
          -  Metastases located within 3 cm of the previously irradiated structures:&#xD;
&#xD;
               1. Spinal cord previously irradiated to &gt; 40 Gy&#xD;
&#xD;
               2. Brachial plexus previously irradiated to &gt; 50 Gy&#xD;
&#xD;
               3. Small intestine, large intestine, or stomach previously irradiated to &gt; 45 Gy&#xD;
&#xD;
               4. Brainstem previously irradiated to &gt; 50 Gy&#xD;
&#xD;
               5. Lung previously irradiated with prior V20Gy &gt; 30%&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean S Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sean S. Park</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

